According to the company, the technology is a highly sensitive and accurate method of detecting and quantifying cellular responses, allowing greater specificity, quantification, and amplification of clinical and commercial opportunities.
The technology underpins the AditxtScore platform, allowing for a standardization of cellular assays.
These assays can then be used as a development platform for clinical utility. Applications of the technology can be used to profile individuals to select appropriate therapies and assess immune status before, during, and after therapeutic intervention.
Aditxt develops technologies focused on improving immune system health through immune monitoring and reprogramming.
Aditxt's immune monitoring technology is designed to provide a personalized, comprehensive system immune system profile.
Aditxt's immune reprogramming technology, currently preclinical, is designed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.
AditxtScore for COVID-19 is Aditxt's proprietary immune profile technology to equip people with information about their level of protection.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary